COMMUNIQUÉS West-GlobeNewswire

MaxCyte Reports Second Quarter 2026 Financial Results
12/08/2026
Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurchased approximately $ [...]
Lumexa Imaging Announces Second Quarter 2026 Results
12/08/2026
RALEIGH, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the second quarter ended June 30, 2026, [...]
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
12/08/2026
Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath ® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Solid Tumors Phase III [...]
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
12/08/2026
SUNNYVALE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
BioStem Technologies Reports Second Quarter 2026 Financial Results
12/08/2026
Generates 29% sequential revenue growth, increasing to $7.9 million; Raises full-year 2026 revenue guidance Uplists to Nasdaq Capital Market POMPANO BEACH, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, [...]
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
12/08/2026
IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in [...]
Kura Oncology Reports Second Quarter 2026 Financial Results
12/08/2026
– KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI ® achieved majority share of new patient starts in R/R NPM1- [...]
Acquisition of Own Shares
12/08/2026
Mechelen, Belgium; 12 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
12/08/2026
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose [...]
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
12/08/2026
Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved Utebzi™ (tebipenem [...]
Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
12/08/2026
Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi ® revenues were $8.1 million for the second quarter of 2026 Strong revenue growth and [...]
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
12/08/2026
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab- [...]
Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones
12/08/2026
PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed sales subject to [...]
Hyperion DeFi Reports 2Q 2026 Financial Results with Another Record Quarterly Net Income and Strong Operating Momentum
12/08/2026
Company Reports Record $31.0M Net Income and $53.7M Adjusted EBITDA ( 8 ) Announcing New HAUS Agreement with Entropy, an Upcoming HIP-3 Deployer 1 Million HYPE Tokens Redeployed to Support HIP-3 & HIP-4 Markets [...]
Earth Science Tech, Inc. (ETST) Expands National Footprint with Strategic Acquisition of California Compounding Pharmacy, Meduvo LLC
12/08/2026
MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on a diversified portfolio, today announced the acquisition of Meduvo LLC, a [...]
Rampart retire son recours contre la décision d’invalidation de l’USPTO
12/08/2026
ST. PAUL, Minnesota, 12 août 2026 (GLOBE NEWSWIRE) -- Egg Medical a annoncé que Rampart IC, LLC (« Rampart ») avait retiré son recours contre la décision de réexamen de l’USPTO, selon laquelle les revendications du [...]
NOTICE TO DISREGARD -- Leading Edge Health Inc
13/08/2026
LAS VEGAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- We are advised by VITALIBOOST LLC that journalists and other readers should disregard the news release, “Load Boost: Semenax, Volume Pills or SemEnhance - Which is Best Load [...]
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
12/08/2026
The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone’s Clinical Pipeline and Planned Commercial Production TORONTO and HAIFA, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc [...]
Park Dental Partners Announces Second Quarter 2026 Results
12/08/2026
MINNEAPOLIS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK) and affiliated dental practices (“Park Dental Partners,” “we,” “our,” “us,” or the “Company”) today reported its second quarter [...]

Pages